← Leaderboards
Fadi N Salloum
Virginia Commonwealth University
$8,358,104
Attributed
$10,364,113
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,364,113 · 8
By mechanism
R35$3,865,725 · 1
R01$3,070,000 · 2
R44$1,993,505 · 1
R43$750,001 · 2
R21$419,375 · 1
T32$265,507 · 1
Top collaborators
- Anindita Das4 shared
- Cathy A Swindlehurst4 shared
- Lauren Ashley Cowart1 shared
- William Gregory Hundley1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Paul Dent$11,860,656
- Cynthia M Bulik$23,077,361
- Anindita Das$3,017,498
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventHeartHeart FailureInjuryCardiacMyocardial IschemiaMyocardial InfarctionInflammasomeIschemiaAttenuatedSignal TransductionDesignAcute Myocardial InfarctionMediatingInflammatoryProgramsInflammationCessation Of LifeCardiomyopathiesCardiovascular DiseasesProductionHeart FunctionCause Of DeathFibrosis
Grant awards (20)
Managing Cardiac Toxicities of Cancer Therapy$776,250
R35 · FY2025 · HL · contact PI
Multi-Disciplinary Training Program in Translational Cardiovascular Research$265,507
T32 · FY2025 · HL
Managing Cardiac Toxicities of Cancer Therapy$760,725
R35 · FY2024 · HL · contact PI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$930,592
R44 · FY2023 · HL
Managing Cardiac Toxicities of Cancer Therapy$776,250
R35 · FY2023 · HL · contact PI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$1,062,913
R44 · FY2022 · HL
Managing Cardiac Toxicities of Cancer Therapy$776,250
R35 · FY2022 · HL · contact PI
Managing Cardiac Toxicities of Cancer Therapy$776,250
R35 · FY2021 · HL · contact PI
Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease$375,000
R43 · FY2021 · HL
Relaxin Signaling in Post-MI Cardiac Inflammation, Adverse Remodeling and Failure$388,125
R01 · FY2020 · HL · contact PI
Hydrogen Sulfide for Prevention and Treatment of Ischemic Heart Failure$381,250
R01 · FY2020 · HL · contact PI
Relaxin Signaling in Post-MI Cardiac Inflammation, Adverse Remodeling and Failure$388,125
R01 · FY2019 · HL · contact PI
Hydrogen Sulfide for Prevention and Treatment of Ischemic Heart Failure$381,250
R01 · FY2019 · HL · contact PI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$375,001
R43 · FY2019 · HL
Relaxin Signaling in Post-MI Cardiac Inflammation, Adverse Remodeling and Failure$387,500
R01 · FY2018 · HL · contact PI
Hydrogen Sulfide for Prevention and Treatment of Ischemic Heart Failure$381,250
R01 · FY2018 · HL · contact PI
Hydrogen Sulfide for Prevention and Treatment of Ischemic Heart Failure$381,250
R01 · FY2017 · HL · contact PI
Targeting Relaxin Receptor 1 for Protection of the Aging Diabetic Heart$190,625
R21 · FY2017 · AG · contact PI
Hydrogen Sulfide for Prevention and Treatment of Ischemic Heart Failure$381,250
R01 · FY2016 · HL · contact PI
Targeting Relaxin Receptor 1 for Protection of the Aging Diabetic Heart$228,750
R21 · FY2016 · AG · contact PI